Insulin resistance is arguably the most consequential metabolic disturbance of our time. It precedes Type 2 diabetes by 10–15 years, underlies non-alcoholic fatty liver disease, polycystic ovary syndrome, hypertension, dyslipidaemia, and accelerates cardiovascular disease. Most people develop it silently, without any symptoms, while their routine fasting glucose remains in the normal range. Understanding insulin resistance — what it is, how to measure it, and how to reverse it — is foundational to preventive metabolic medicine.

What Is Insulin Resistance?

Insulin is a peptide hormone secreted by pancreatic beta cells in response to rising blood glucose. Its primary role is to facilitate glucose uptake into cells — particularly skeletal muscle (which accounts for 75–80% of post-meal glucose disposal), the liver (which stores glucose as glycogen), and adipose tissue (which uses glucose for triglyceride synthesis).^[1]

Insulin resistance develops when these target tissues lose their sensitivity to insulin signalling. The insulin receptor is still present, but the downstream intracellular signalling cascade — involving IRS-1 phosphorylation, PI3K activation, and GLUT4 translocation to the cell membrane — becomes impaired.^[2] The cell no longer efficiently extracts glucose from the bloodstream in response to normal insulin concentrations.

The pancreas compensates by secreting more insulin — a state called hyperinsulinaemia. For years, blood glucose appears normal because the pancreas is producing 2–5 times the usual amount of insulin to maintain it. It is only when beta cells can no longer sustain this compensation that fasting glucose rises and diabetes is diagnosed. But the underlying metabolic derangement has been present for over a decade.^[3]

The Upstream Causes of Insulin Resistance

Insulin resistance is driven by a convergence of factors:

• Ectopic fat accumulation: Excess lipid deposition in the liver (hepatic steatosis) and skeletal muscle interferes directly with insulin signalling by activating protein kinase C isoforms that phosphorylate IRS-1 on serine residues rather than tyrosine, impairing the signalling cascade.^[4]
• Chronic low-grade inflammation: Visceral adipose tissue secretes pro-inflammatory cytokines — TNF-α and IL-6 in particular — that directly inhibit insulin receptor signalling in muscle and liver.^[5]
• Mitochondrial dysfunction: Impaired mitochondrial oxidative capacity in skeletal muscle reduces the ability to oxidise fatty acids, leading to intramyocellular lipid accumulation and insulin resistance.^[6]
• Gut microbiome dysbiosis: Altered gut microbiota composition affects short-chain fatty acid production, intestinal permeability (increasing LPS translocation and systemic inflammation), and bile acid metabolism — all of which modulate insulin sensitivity.^[7]
• Sleep deprivation and cortisol excess: A single night of 4 hours of sleep raises cortisol sufficiently to reduce peripheral insulin sensitivity by 30–40% the following day.^[8]

The Downstream Cascade: What Hyperinsulinaemia Does

Chronically elevated insulin has profound systemic consequences beyond glucose dysregulation:^[9,10]

• Visceral fat accumulation: Insulin is a potent anabolic hormone that promotes fat storage, particularly in visceral depots which express high concentrations of insulin receptors.
• Dyslipidaemia: Hyperinsulinaemia stimulates hepatic VLDL-triglyceride production, raises small dense LDL particles, and suppresses HDL.
• Hypertension: Insulin promotes renal sodium retention and activates the sympathetic nervous system, raising blood pressure.
• PCOS: Hyperinsulinaemia stimulates ovarian androgen production, disrupting the LH/FSH ratio and driving the hormonal profile of polycystic ovary syndrome.
• Non-alcoholic fatty liver disease: Hepatic insulin resistance drives excess de novo lipogenesis in the liver.
• Cancer risk: Insulin and IGF-1 are potent mitogenic signals. Chronic hyperinsulinaemia has been associated with increased risk of breast, colorectal, endometrial, and pancreatic cancers.^[11]

Measuring Insulin Resistance: The HOMA-IR Score

The gold standard for measuring insulin resistance is the hyperinsulinaemic-euglycaemic clamp, a technically demanding research procedure. For clinical practice, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the validated surrogate:^[12]

HOMA-IR = (Fasting Insulin [mIU/L] × Fasting Glucose [mmol/L]) ÷ 22.5

Or in mg/dL units: HOMA-IR = (Fasting Insulin × Fasting Glucose) ÷ 405

Interpretation: Below 1.0 is optimal; 1.0–2.0 is normal; 2.0–2.5 is borderline; above 2.5 is significant insulin resistance requiring intervention. HOMA-IR above 3.0 correlates strongly with metabolic syndrome and predictsa 5–10 times higher risk of developing Type 2 diabetes within 5 years.^[13]

Importantly, HOMA-IR detects insulin resistance years before HbA1c or fasting glucose become abnormal. We routinely test fasting insulin as part of our metabolic panel — a test that is conspicuously absent from most standard annual health checks.

Reversing Insulin Resistance: The Evidence-Based Interventions

Insulin resistance is highly responsive to lifestyle intervention. The interventions with the strongest evidence, ranked by magnitude of HOMA-IR reduction in clinical trials:

1. Significant weight loss (10%+ body weight): Reduces HOMA-IR by 40–60% through reduction of ectopic fat and visceral adiposity.^[14]
2. Progressive resistance training: Increases GLUT4 expression in skeletal muscle independently of weight loss, improving insulin-mediated glucose disposal by 25–40%.^[15]
3. Low-carbohydrate diet (<130g/day): Reduces postprandial insulin demand directly; HOMA-IR reductions of 30–45% reported at 12 weeks.^[16]
4. Time-restricted eating: Improves insulin sensitivity through circadian alignment of glucose metabolism; HOMA-IR reductions of 15–25% at 12 weeks.^[17]
5. Sleep optimisation (7–9 hours): Reverses cortisol-mediated insulin resistance within days of improved sleep quality.^[8]
6. Metformin: Reduces hepatic glucose output; 15–20% HOMA-IR reduction. Useful adjunct but inferior to lifestyle change as monotherapy.^[18]

Body fat is not simply an inert energy store. It is a biologically active endocrine organ that secretes hormones, inflammatory cytokines, and free fatty acids — and its health consequences depend critically on where it is located. Visceral fat — the fat that wraps around abdominal organs — is metabolically aggressive, pro-inflammatory, and the primary driver of metabolic syndrome, insulin resistance, cardiovascular disease, and Type 2 diabetes. Subcutaneous fat — the fat under the skin — is comparatively benign. Understanding this distinction is fundamental to accurate cardiometabolic risk assessment.

Two Fat Compartments: Anatomy and Biology

The human body stores fat in two principal anatomical compartments:

Subcutaneous adipose tissue (SAT) lies directly beneath the dermis, distributed across the thighs, buttocks, upper arms, and trunk. It comprises approximately 80–85% of total body fat in most individuals. SAT functions primarily as a long-term energy reserve and provides thermal insulation and mechanical cushioning. SAT adipocytes produce leptin, adiponectin, and estrogen precursors — hormones with largely beneficial metabolic effects.^[1]

Visceral adipose tissue (VAT) is located within the abdominal cavity: the omentum (the large fat apron in the peritoneum), mesenteric fat (around the intestines), and peri-organ fat around the liver, pancreas, and kidneys. Despite comprising only 10–20% of total body fat, VAT exerts a disproportionate metabolic influence due to its anatomical location, distinct cellular biology, and direct drainage into the portal circulation.^[2]

The Portal Drainage Hypothesis: Why VAT Location Is So Dangerous

The anatomical key to VAT’s metabolic danger is its venous drainage. Unlike subcutaneous fat, which drains into the systemic circulation, visceral fat drains directly via the portal vein into the liver. This means that all the free fatty acids (FFAs), cytokines, and adipokines released by visceral adipocytes arrive directly at the liver in high concentration, before dilution in systemic circulation.^[3]

This portal FFA flux drives:^[4]

• Hepatic insulin resistance: Excess FFA delivery activates hepatic protein kinase C-ε, impairing insulin receptor signalling and driving excess hepatic glucose output.
• Non-alcoholic fatty liver disease (NAFLD/MASLD): The liver’s limited capacity to oxidise the FFA flux leads to triglyceride accumulation within hepatocytes.
• VLDL overproduction: The liver exports excess lipid as VLDL-triglycerides, raising plasma triglycerides and promoting small dense LDL formation.
• Hyperinsulinaemia: To overcome hepatic insulin resistance, the pancreas secretes more insulin, creating a systemic hyperinsulinaemic state with all its downstream consequences.

Visceral Fat as an Endocrine Organ: The Adipokine Cascade

Visceral adipocytes have a distinct secretory profile compared to subcutaneous adipocytes. They produce:^[5,6]

• TNF-α (tumour necrosis factor-alpha): A pro-inflammatory cytokine that inhibits insulin receptor signalling and promotes apoptosis. VAT secretes 5–10 times more TNF-α per gram than SAT.
• IL-6 (interleukin-6): Drives hepatic CRP production, promoting systemic inflammation and endothelial dysfunction.
• PAI-1 (plasminogen activator inhibitor-1): Impairs fibrinolysis, increasing thrombosis risk and contributing to cardiovascular events.
• Resistin: Promotes insulin resistance in hepatic and skeletal muscle tissue.
• Reduced adiponectin: Unlike the above, adiponectin is protective — it improves insulin sensitivity, reduces hepatic fat, and has anti-inflammatory effects. Visceral obesity is associated with paradoxically low adiponectin despite abundant fat mass.

The Metabolically Obese Normal Weight (MONW) Phenotype

Perhaps the most clinically important implication of the VAT-SAT distinction is the existence of metabolically obese normal weight (MONW) individuals — people with BMI in the normal range who nonetheless carry significant visceral fat and display full metabolic syndrome.^[7] This phenotype is particularly prevalent in South Asian, East Asian, and Middle Eastern populations, who carry higher proportions of visceral fat at any given BMI compared to European populations.

Conversely, the metabolically healthy obese (MHO) phenotype describes individuals with high BMI who carry their excess fat predominantly subcutaneously, with comparatively low visceral fat and preserved insulin sensitivity. Though MHO status is not fully protective and tends to deteriorate with age, these individuals have dramatically lower short-term metabolic risk than those with equivalent BMI but high VAT.^[8]

Measuring Visceral Fat: From Simple to Precise

Measurement options, from least to most precise:^[9]

1. Waist circumference: The simplest proxy. In South Asian and Middle Eastern populations, cardiometabolic risk rises at waist circumferences above 90cm (men) and 80cm (women) — significantly lower than the Western thresholds of 102cm/88cm.
2. Waist-to-height ratio: A waist circumference above 50% of height is a reliable indicator of elevated visceral fat risk across all ethnicities.
3. Waist-to-hip ratio: Ratio above 0.90 (men) or 0.85 (women) indicates central adiposity.
4. DEXA scan (dual-energy X-ray absorptiometry): Provides precise fat distribution data, distinguishing VAT and SAT compartments.
5. Abdominal MRI or CT: The gold standard for visceral fat quantification in research settings.

Reducing Visceral Fat: What Works

Visceral fat is more responsive to caloric restriction and exercise than subcutaneous fat. Targeted reductions:^[10,11]

• Caloric restriction: VAT is preferentially mobilised in the first weeks of caloric restriction. A 5% total body weight loss produces a 10–15% reduction in visceral fat volume.
• Aerobic exercise: Even without weight loss, 30 minutes of moderate aerobic exercise 5 days per week reduces visceral fat by 3–6% over 12 weeks.
• Resistance training: Reduces VAT through improved insulin sensitivity and increased resting metabolic rate.
• Sleep: As discussed in our sleep article, inadequate sleep specifically promotes visceral fat accumulation via cortisol dysregulation.
• SGLT2 inhibitors and GLP-1 agonists: Both drug classes preferentially reduce visceral fat disproportionately to overall weight loss.